Arcutis Biotherapeutics (ARQT) Times Interest Earned (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Times Interest Earned of -$2.07 for Q1 2026, up 74.74% year-over-year from -$1.18 in Q1 2025, and down 128.54% quarter-over-quarter from $7.24 in Q4 2025.
Arcutis Biotherapeutics (ARQT) Times Interest Earned (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Times Interest Earned history runs 8 years deep, the most recent figure standing at -$2.07 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 74.74% year-over-year to -$2.07; the TTM figure through Mar 2026 stood at $0.25 (up 105.09% YoY), while the FY2025 annual figure was -$0.05, up 90.45% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$2.07, down from $7.24 in the prior quarter.
- The five-year high for Times Interest Earned was $7.24 in Q4 2025, with the low at -$34.07 in Q1 2022.
- The 5-year median for Times Interest Earned is -$6.68 (2024), against an average of -$9.23.
- Peak annual rise in Times Interest Earned reached 850.74% in 2025, while the deepest fall reached 93.92% in 2025.
- Arcutis Biotherapeutics' Times Interest Earned stood at -$17.55 in 2022, then jumped by 55.09% to -$7.88 in 2023, then jumped by 87.76% to -$0.96 in 2024, then jumped by 850.74% to $7.24 in 2025, then plunged by 128.54% to -$2.07 in 2026.
- Business Quant data shows ARQT's Times Interest Earned at -$2.07 in Q1 2026, $7.24 in Q4 2025, and $2.75 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 0.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.16 |
| Mar 31, 2026 | -2.07 |
| Dec 31, 2025 | 7.24 |
| Sep 30, 2025 | 2.75 |
| Jun 30, 2025 | -0.36 |
| Mar 31, 2025 | -8.18 |
| Dec 31, 2024 | -0.96 |
| Sep 30, 2024 | -5.87 |
| Jun 30, 2024 | -6.68 |
| Mar 31, 2024 | -4.22 |
| Dec 31, 2023 | -7.88 |
| Sep 30, 2023 | -4.86 |
| Jun 30, 2023 | -9.02 |
| Mar 31, 2023 | -10.83 |
| Dec 31, 2022 | -17.55 |
| Sep 30, 2022 | -21.38 |
| Jun 30, 2022 | -32.91 |
| Mar 31, 2022 | -34.07 |
| Dec 31, 2021 | -625.32 |
| Dec 31, 2020 | 236.56 |